Table 2.
Pathway enrichment for convergent propranolol DEGs in both DAOYs and NPCs.
| Source | Term | Q value |
|---|---|---|
| CORUM | PA700 complex | 0.007 |
| CORUM | p54(nrb)-PSF-matrin3 complex | 0.007 |
| CORUM | PA700-20S-PA28 complex | 0.013 |
| CORUM | HEXIM1-DNA-PK-paraspeckle components-ribonucleoprotein complex | 0.051 |
| CORUM | Ubiquitin E3 ligase (CHEK1, CUL4A) | 0.065 |
| CORUM | CORUM root | 0.077 |
| CORUM | EBAFb complex | 0.089 |
| CORUM | NCOR1 complex | 0.089 |
| KEGG | Proteasome | 0.009 |
| KEGG | Spinocerebellar ataxia | 0.027 |
| KEGG | Prion disease | 0.047 |
| KEGG | Protein processing in endoplasmic reticulum | 0.053 |
| KEGG | Hippo signaling pathway—multiple species | 0.090 |
| MIRNA | hsa-miR-6766-5p | 4.37E-04 |
| MIRNA | hsa-miR-6756-5p | 4.37E-04 |
| MIRNA | hsa-miR-539-5p | 4.39E-04 |
| MIRNA | hsa-miR-4668-3p | 0.007 |
| MIRNA | hsa-miR-21-5p | 0.013 |
| MIRNA | hsa-miR-654-5p | 0.021 |
| MIRNA | hsa-miR-541-3p | 0.027 |
| MIRNA | hsa-miR-1468-3p | 0.044 |
| MIRNA | hsa-let-7b-5p | 0.046 |
| MIRNA | hsa-miR-548f-5p | 0.051 |
| MIRNA | hsa-miR-548aj-5p | 0.055 |
| MIRNA | hsa-miR-548x-5p | 0.055 |
| MIRNA | hsa-miR-548g-5p | 0.055 |
| MIRNA | hsa-miR-193b-3p | 0.055 |
| REAC | Transcriptional regulation by RUNX1 | 2.26E-04 |
| REAC | Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 0.001 |
| REAC | Cellular response to hypoxia | 0.004 |
| REAC | Host Interactions of HIV factors | 0.004 |
| REAC | Cell Cycle Checkpoints | 0.007 |
| REAC | UCH proteinases | 0.007 |
| REAC | G2/M Checkpoints | 0.012 |
| REAC | Regulation of ornithine decarboxylase (ODC) | 0.012 |
| REAC | G1/S DNA Damage Checkpoints | 0.013 |
| REAC | Signaling by NOTCH | 0.014 |
| REAC | p53-Independent G1/S DNA damage checkpoint | 0.015 |
| REAC | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 0.015 |
| REAC | p53-Independent DNA Damage Response | 0.015 |
| REAC | Regulation of APC/C activators between G1/S and early anaphase | 0.015 |
| REAC | Regulation of Apoptosis | 0.017 |
| REAC | Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 0.021 |
| REAC | Assembly of the pre-replicative complex | 0.023 |
| REAC | Deubiquitination | 0.024 |
| REAC | Autodegradation of Cdh1 by Cdh1:APC/C | 0.024 |
| REAC | APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfaction of the cell cycle checkpoint | 0.025 |
| REAC | Regulation of MECP2 expression and activity | 0.029 |
| REAC | Stabilization of p53 | 0.031 |
| REAC | APC/C:Cdc20 mediated degradation of mitotic proteins | 0.033 |
| REAC | DNA Replication Pre-Initiation | 0.033 |
| REAC | Orc1 removal from chromatin | 0.034 |
| REAC | PTEN Regulation | 0.034 |
| REAC | Metabolism of polyamines | 0.036 |
| REAC | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 0.038 |
| REAC | Regulation of mitotic cell cycle | 0.040 |
| REAC | APC/C-mediated degradation of cell cycle proteins | 0.040 |
| REAC | Transcriptional regulation by RUNX3 | 0.040 |
| REAC | CDT1 association with the CDC6:ORC:origin complex | 0.041 |
| REAC | MAPK6/MAPK4 signaling | 0.042 |
| REAC | Ub-specific processing proteases | 0.043 |
| REAC | Switching of origins to a post-replicative state | 0.043 |
| REAC | APC/C:Cdc20 mediated degradation of Securin | 0.045 |
| REAC | Vpu mediated degradation of CD4 | 0.054 |
| REAC | Cross-presentation of soluble exogenous antigens (endosomes) | 0.072 |
| REAC | Regulation of activated PAK-2p34 by proteasome mediated degradation | 0.072 |
| REAC | Hedgehog ligand biogenesis | 0.074 |
| REAC | p53-Dependent G1/S DNA damage checkpoint | 0.082 |
| REAC | p53-Dependent G1 DNA Damage Response | 0.082 |
| REAC | SCF-beta-TrCP mediated degradation of Emi1 | 0.087 |
| REAC | CDK-mediated phosphorylation and removal of Cdc6 | 0.091 |
| REAC | Autodegradation of the E3 ubiquitin ligase COP1 | 0.095 |
| REAC | Ubiquitin-dependent degradation of Cyclin D | 0.095 |
| WP | mRNA Processing | 0.004 |
| WP | CAMKK2 Pathway | 0.004 |
| WP | Pathways Affected in Adenoid Cystic Carcinoma | 0.017 |
| WP | MET in type 1 papillary renal cell carcinoma | 0.024 |
| WP | Oncostatin M Signaling Pathway | 0.078 |
| WP | 15q13.3 copy number variation syndrome | 0.080 |
| WP | Gastrin Signaling Pathway | 0.090 |